Personal stories

Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.

Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to inflammatory bowel disease, psoriasis and rheumatoid arthritis, among other immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.

Here’s an infographic breakdown of the company’s second-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.

Health workers and first responders bear a double burden as survivors themselves, dealing with their own losses while helping their communities recover and rebuild in the aftermath of a disaster.

Eleven high school students from New Jersey—each representing a different congressional district—traveled to Washington, D.C., earlier this year to participate in the Close Up Foundation’s Washington, D.C. civic engagement program as Johnson & Johnson Scholars.

A Johnson & Johnson scientist explains how the new Acuvue® Oasys Max 1-Day Multifocal for Astigmatism contact lens also filters blue light, supports the eye’s natural tear film and helps eyes easily switch focus from distance to reading.

Warm autoimmune hemolytic anemia (wAIHA) causes fatigue so profound, it can limit the lives of people who have the condition. Learn more about this rare disease and a potential targeted treatment developed by Johnson & Johnson that’s currently in clinical trials.

Behind every innovative medicine, treatment and therapy is a clinical trial. To help you understand them better, here’s a closer look at how they work.

Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 50 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.